Biodistribution study of ^99mTc-gemcitabine-loaded spherulites in Sprague–Dawley rats by gamma scintigraphy to investigate its lung targeting potential

References

• Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarasoff P, Satterlee W, Raber MN. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol, 1991;9(3):491–8.
   PubMed Web of Science ®Google Scholar
• Briuglia M, Rotella C, McFarlane A, Lamprou D. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res, 2015;5(3):231–42.
   PubMed Web of Science ®Google Scholar
• Chitkara D, Mittal A, Behrman SW, Kumar N, Mahato RI. Self-assembling, amphiphilic polymer–gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma. Bioconjugate Chem, 2013; 24(7):1161–73.
   PubMed Web of Science ®Google Scholar
• Das S, Desai JL, Thakkar HP. Gemcitabine hydrochloride-loaded functionalised carbon nanotubes as potential carriers for tumour targeting. Indian J Pharm Sci, 2013;75(6):707–15.
   PubMed Web of Science ®Google Scholar
• Dhand C, Prabhakaran MP, Beuerman RW, Lakshminarayanan R, Dwivedi N, Ramakrishna S. Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery. RSC Adv, 2014; 4(62):32673–89.
   Web of Science ®Google Scholar
• Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 2). Trop J Pharm Res, 2013; 12(2):265–73.
   Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed, 2006;1(3):297–315.
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today, 2006;11(17):812–8.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Ashton P, Pearson PA. Intraocular drug delivery. Boca Raton, FL: CRC Press, 2006: ISBN-13: 978-1-4200-1650-5
   Google Scholar
• Kudgus RA, Walden CA, McGovern RM, Reid JM, Robertson JD, Mukherjee P. Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component. Sci Rep, 2014;2014:4. Article number: 5669.
   Google Scholar
• Manegold C. Gemcitabine (Gemzar®) in non-small cell lung cancer. Expert Rev Anticancer Ther, 2004;4(3):345–60.
   PubMedGoogle Scholar
• Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev, 2011;63(3):161–9. 2011;
   PubMed Web of Science ®Google Scholar
• Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab, 2012;13(1):105–19.
   PubMed Web of Science ®Google Scholar
• Molina J, Yang P, Cassivi S, Schild S, Adjei A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 2008;5(83):584–94.
   Google Scholar
• Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomed, 2010;5:101–8.
   PubMed Web of Science ®Google Scholar
• Patel A, Tyagi A, Sharma RK, Thakkar H. A gamma scintigraphy study to investigate uterine targeting efficiency of raloxifene-loaded liposomes administered intravaginally in New Zealand white female rabbits. Drug Deliv, 2016;23(9):3330–8. 2016;
   PubMed Web of Science ®Google Scholar
• Philippot JR, Schuber F. Liposomes as tools in basic research and industry. Boca Raton, FL: CRC Press, 1994.
   Google Scholar
• Pitrubhakta AB, Shinde AJ, Jadhav NR. Design, development and characterization of pegylated liposomes of gemcitabine hydrochloride. Der Pharm Lett, 2012;4:314–29.
   Google Scholar
• Ranade VV, Cannon JB. Drug delivery systems. Boca Raton, FL: CRC Press, 2011: ISBN-9781439806180.
   Google Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. Faseb J, 2008;22(3):659–61.
   PubMed Web of Science ®Google Scholar
• Richard A, Delvaux J, Bourel-Bonnet L. Effects of sterilizing-grade filters on the physico-chemical properties of onion-like vesicles. Int J Pharm, 2006;312(1):144–50.
   PubMed Web of Science ®Google Scholar
• Saha GB. Physics and radiobiology of nuclear medicine. Berlin, Germany: Springer Science & Business Media, 2010: ISBN 978-1-4614-4012-3.
   Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release, 2010; 145(3):182–95.
   PubMed Web of Science ®Google Scholar
• Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 2000;18(1):122–122.
   Web of Science ®Google Scholar
• Shah R, Eldridge D, Palombo E, Harding I. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci, 2014;25(1):59–75.
   Google Scholar
• Shukla SK. Technetium in biology and medicine. Inor Chim Acta, 1983;79:286.
   Web of Science ®Google Scholar
• Simard P, Hoarau D, Khalid M, Roux E, Leroux J. Preparation and in vivo evaluation of PEGylated spherulite formulations. BBA Biomembranes, 2005;1715(1):37–48.
   PubMed Web of Science ®Google Scholar
• Singh T, Kumar N, Soni S, Rawat H, Mittal G, Singh AK, Bhatnagar A. A new method for radiolabeling of human immunoglobulin-G and its biological evaluation. J Pharm Bioallied Sci, 2012; 4(4):286–90.
   PubMedGoogle Scholar
• Soni N, Jain K, Gupta U, Jain NK. Controlled delivery of gemcitabine hydrochloride using mannosylated poly (propyleneimine) dendrimers. J Nanopart Res, 2015;17(11):1–17.
   Web of Science ®Google Scholar
• Sudha R, Mittal G, Chutani K, Sharma RK. Chap. 6: Nuclear scintigraphy: a promising tool to evaluate novel and nano-based drug delivery systems. In: Vol. IV - Nanotheranostics, 2013:165–85.
   Google Scholar
• Thakkar H, Dhande R. Pegylated spherulites of anticancer active ingredients. Indian Patent, 2016; Application No. 201621027691.
   Google Scholar
• Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK. Drug delivery systems: an updated review. Int J Pharm Investig, 2012;2(1):2–11.
   PubMedGoogle Scholar
• Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release, 2002;78(1):15–24.
   PubMed Web of Science ®Google Scholar
• Yuan F, Dellian D, Fukumura D, Leunig M, Berk DA, Torchillin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res, 1995;55(17):3752–6.
   PubMed Web of Science ®Google Scholar
• Zhang P, Huang Y, Makhov A, Gao X, Zhang P, Li S. Characterization of spherulites as a lipidic carrier for low and high molecular weight agents. Pharm. Res, 2013;30(6):1525–35.
   PubMed Web of Science ®Google Scholar
• Zolle I. Technetium-99m pharmaceuticals. Berlin, Heidelberg: Springer, 2007: ISBN-978-3-540-33990-8.
   Google Scholar